Addressing phenoconversion: the Achilles' heel of personalized medicine.
about
Pharmacokinetic drug interactions in liver disease: An updateImpact of New Genomic Technologies on Understanding Adverse Drug ReactionsFrom Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized MedicinePotential role of patients' CYP3A-status in clozapine pharmacokinetics.In vitro study of the variable effects of proton pump inhibitors on voriconazolePersonalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype.Alternative Sampling Strategies for Cytochrome P450 Phenotyping.Normalizing sleep quality disturbed by psychiatric polypharmacy: a single patient open trial (SPOT).Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.CYP3A activity: towards dose adaptation to the individual.Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.Use of microdose phenotyping to individualise dosing of patients.Phenoconversion and therapeutic drug monitoring.Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice.Precision medicine: does ethnicity information complement genotype-based prescribing decisions?Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children.High CYP2C19 phenotypic variability in gastrointestinal cancer patients.Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation.Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients.CYP450 genotype and pharmacogenetic association studies: a critical appraisalNo Effect of Dose Adjustment to the Genotype in Patients With Severe Mental Illness
P2860
Q26774479-3B9B9EFC-2A61-4FF5-83DE-A093ED056DE6Q26787099-1CD5F254-E2BF-4EA4-AA2E-02DA1539CA54Q28067029-3E838346-D9CB-4EA5-B14F-CF69B17FC3BCQ33858281-F1354409-615A-4A08-9E4E-D73E87657591Q35960842-9BE94B22-2F49-4311-BF3C-823792784948Q36410101-F296A986-83A0-47D9-9CBD-C9DCC7E6EA7CQ37547290-85A201B6-C504-4451-BCDF-C9F802B3956CQ38560254-5C6503CF-A180-4158-B5D9-901D7A0ABB97Q38637946-442947AD-AC79-478C-B809-A039758EBC8FQ38734067-6E1B9C13-10B9-4AE0-9892-2EFE8C1E4A59Q38763583-29B77068-EA80-4122-B53C-93597EFC649EQ38848409-024EDEFC-6804-4066-8569-7B5732AC849EQ40772216-BB53BF30-FD77-41E5-9724-7086D79FCCA1Q40996401-61A8533E-A2A8-4108-9221-9428A0965443Q43157879-53C2F816-0080-422B-B823-12D9EADD913CQ44123954-2C64255A-A232-4D07-A769-73F15CF598EEQ47566249-C44FA739-E77F-4066-A11A-9747A60B6C1FQ47657184-43FC6BF5-0774-4AC6-A1A0-9E6B9E0701C4Q47894175-40C28D6B-8E98-4D74-99A6-21E139E6E402Q47937029-36DE1BD7-3B68-4EB8-A9E0-D0569E0AB83AQ47978860-C5824201-961A-42AB-837F-FA4C0F429B98Q50271114-84AB3BB1-5DED-4341-A7C0-9FC17C9B3693Q50854235-C62AEB5C-4C53-4412-9DD2-F40902D18EBBQ55129457-C9E4879C-10B0-4B37-B391-E1FDDBBA0AD4Q55439721-72CE57EB-AA8D-40C3-B0C7-F156419ACF73Q57585515-3CB86CEA-14B9-4877-8A53-B7D29F7DD48EQ58797266-12A4BB9C-834D-4AD2-9B33-60F6F422E607
P2860
Addressing phenoconversion: the Achilles' heel of personalized medicine.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Addressing phenoconversion: the Achilles' heel of personalized medicine.
@ast
Addressing phenoconversion: the Achilles' heel of personalized medicine.
@en
type
label
Addressing phenoconversion: the Achilles' heel of personalized medicine.
@ast
Addressing phenoconversion: the Achilles' heel of personalized medicine.
@en
prefLabel
Addressing phenoconversion: the Achilles' heel of personalized medicine.
@ast
Addressing phenoconversion: the Achilles' heel of personalized medicine.
@en
P2860
P356
P1476
Addressing phenoconversion: the Achilles' heel of personalized medicine.
@en
P2093
Rashmi R Shah
Robert L Smith
P2860
P304
P356
10.1111/BCP.12441
P407
P577
2015-02-01T00:00:00Z